Tucatinib, Trastuzumab and Capecitabine With Brain and/or Spinal Radiotherapy (XRT) in Patients With HER2+, HER2 Mutated and/or HER2-amplified Metastatic Breast Cancer and Leptomeningeal Disease: A Multi-centre Phase II, Single Arm Feasibility Study

Trial Details

NCT ID

NCT06016387

Phase

PHASE2

Sponsor

Sunnybrook Health Sciences Centre

Status

RECRUITING

Cancer Type

HER2 Positive Breast Cancer

Interventions

• Tucatinib 150 MG
• Trastuzumab
• Capecitabine
• Brain & Spinal Radiation

Locations (sample)

• Ottawa, Ontario, Canada|45.41117,-75.69812
• Toronto, Ontario, Canada|43.70643,-79.39864

Key Eligibility Criteria

• Men or women with HER2+, HER2 mutated and/or HER2-amplified metastatic breast cancer. HER2+ status will be defined in accordance with ASCO-CAP 2018…
• Evidence of LMD\* in the brain and/or spine (either positive cerebral spinal fluid cytology and/or magnetic resonance imaging evidence of LMD). Mea…
• Age 18+ at time of consent;
• More than 14 days or 5 half-lives from the last dose of any experimental agent is required, whichever is greater;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.